Annuncio • Feb 13
BioGaia AB (publ), Annual General Meeting, May 07, 2026 BioGaia AB (publ), Annual General Meeting, May 07, 2026. Annuncio • Oct 13
BioGaia AB (publ) to Report Q3, 2025 Results on Oct 22, 2025 BioGaia AB (publ) announced that they will report Q3, 2025 results at 8:00 AM, Central European Standard Time on Oct 22, 2025 Annuncio • Aug 22
BioGaia AB (publ) Elects Mauricio Graber as New Board Member and Chairman of the Board At an extraordinary general meeting of BioGaia AB (publ) on 22 August 2025, it was resolved to elect Mauricio Graber as new board member and chairman of the board, following Peter Rothschild's decision to resign as board member and chairman. Annuncio • Jul 25
Biogaia AB (Publ) Announces Resignation of Peter Rothschild as Chairman of the Board and Leave the Board of Directors, Effective At the Extraordinary General Meeting, 22 August 2025 BioGaia AB (publ) announced that Peter Rothschild has announced that he will resign as Chairman of the Board and leave the Board of Directors at the Extraordinary General Meeting, 22 August 2025. Annuncio • Mar 21
Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B) Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B) for SEK 756 million on March 20, 2025. The purchase price amounts to SEK 136.33 for each current class A share and SEK 115 for each class B share. Under the transaction, Anatom will acquire 1,776,758 class A shares and 2,273,600 class B shares (including to-be-converted class A shares) (in total, 4.0% of the total number of shares and 16.0% of the total number votes after the share conversion). The other separate entities, owned by a different member of the Kahane family, will acquire 888,380 class A shares and 1,136,800 class B shares (including to-beconverted class A shares) (in total, 2.0% of the total number of shares and 8.0% of the total number votes after the share conversion).
After the transaction, including existing shareholdings, Anatom will own 1,776,758 class A shares and 5,580,775 class B shares (7.3% of the total number of shares and 18.7% of the total number votes) and the other separate entities, owned by a different member of the Kahane family, will own 888,380 class A shares and 2,809,438 class B shares (3.7% of the total number of shares and 9.3% of the total number votes). The purchase by Anatom is conditional on approval by the Swedish Inspectorate of Strategic Products. Such approval is expected in a few weeks. The Annual General Meeting of BioGaia
The sellers have engaged Rothschild & Co Nordic AB as financial advisor and Vinge as legal advisor in connection with the transaction. Annwall & Rothschild Investments Ab, David Dangoor and others have engaged Gernandt & Danielsson as legal advisor in connection with the transaction. Annuncio • Feb 26
BioGaia AB (publ) announces Annual dividend, payable on May 14, 2025 BioGaia AB (publ) announced Annual dividend of SEK 1.9500 per share payable on May 14, 2025, ex-date on May 08, 2025 and record date on May 09, 2025. Annuncio • Dec 06
BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTION BioGaia announced launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia's product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and enhancing gastrointestinal health. The product's twice-daily dosing supports individuals with occasional gut discomfort in regaining control over their digestive health. Vegan capsule and free from sweeteners, lactose, and gluten, BioGaia® Gastrus® PURE ACTION is certified as FODMAP-friendly and designed for sensitive stomachs. These are a group of short-chain carbohydrates and sugar alcohols found in many common foods. They are poorly absorbed in the small intestine, leading to fermentation by gut bacteria, which can cause symptoms like bloating, gas, and diarrhea, especially in people with irritable bowel syndrome (IBS) or other digestive sensitivities. A low-FODMAP diet is often recommended by healthcare professionals to manage symptoms of IBS and other functional gastrointestinal disorders. Product availability: Finland is the first country to launch BioGaia® Gastrus® PURE ACTION, with more country launches to follow. In Finland, the product is available in Pharmacies and main online Pharmacies. Supported by clinical research: The product has been tested in clinical trials and proven to be safe and effective in relieving symptoms like abdominal pain, gas, and bloating. Probiotics in this blend are proven to withstand the harsh conditions of digestive system, ensuring they reach gut alive. The efficacy of BioGaia® Gastrus® PURE ACTION's ingredients was recently evaluated in a randomized, double-blind, placebo-controlled trial involving 140 adults aged 18-65, diagnosed with IBS based on Rome IV criteria. Participants who used the product demonstrated: Significant reduction in IBS symptoms: A notable improvement in the GSRS-IBS score from week 6 onward, with key symptoms such as abdominal pain, bloating, and gas showing marked relief. Enhanced Quality of Life: Participants using BioGaia® Gastrus® PURE ACTION reported significantly higher Quality of Life (QoL-IBS) scores compared to those on the placebo. Reduced inflammation: While not a defining feature of IBS, the study showed that Gastrus reduced low-grade gut inflammation. A second study on the same strain combination suggested it also lowered systemic low-grade inflammation. Annuncio • Oct 22
BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025 BioGaia AB (publ) announced that they will report Q2, 2025 results at 8:00 AM, Central European Standard Time on Jul 18, 2025 Annuncio • Jul 23
BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025 BioGaia AB (publ) announced that they will report fiscal year 2024 results at 8:00 AM, Central European Standard Time on Feb 12, 2025 Annuncio • Oct 17
Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023 BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%. Annuncio • Sep 26
Biogaia AB (Publ) Appoints Theresa Agnew as CEO BioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson. Annuncio • Sep 02
BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in Sweden BioGaia AB (publ) introduces Prodentis for kids, an apple-flavored lozenge with probiotics and xylitol for oral health, to complement the daily toothbrushing routine. A new addition to the oral health category. Most kids enjoy snacking in between meals, often prefer sugary foods, and have varying enthusiasm for toothbrushing. These habits can lead to unhealthy oral hygiene. Prodentis KIDS contains BioGaia's patented clinically proven probiotic strains L. reuteri ATCC PTA 5289 and L. reuteri DSM 17938 that help the good microorganisms keep a natural balance in the mouth. Prodentis KIDS is specially developed to complement daily toothbrushing routine. From August 2023, Prodentis KIDS will be available for purchase via BioGaia's Swedish webshop, www.biogaia.se as well as the online pharmacies MEDS and Apotea. The recommended retail price is SEK 199. Annuncio • Aug 03
BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023 BioGaia's board of directors has appointed Theresa P. Agnew as the new chief executive officer. Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson & Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College. At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide. Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale. Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements. Annuncio • Jul 06
BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults A randomised, triple-blinded, placebo-controlled study with BioGaia's probiotic Protectis was shown to increase SARS-CoV-2 antibody titres in healthy volunteers when 28 days or more had elapsed from vaccination. It suggests that probiotic supplementation may enhance the long-term protection against breakthrough infections. The study included 159 healthy adults without prior SARS-CoV-2 infection or COVID-19 vaccination. The participants consumed either BioGaia Protectis (Limosilactobacillus reuteri DSM 17938) + 10 microgram vitamin D3, or a placebo product that contained only vitamin D3 for 6 months. During the intervention period 12 subjects were infected, and 17 were fully vaccinated and sampled 28 days or more postvaccination. The purpose of the study was to investigate the effect of probiotic supplementation of BioGaia Protectis on SARS-CoV-2 specific antibody responses after natural infection or vaccination. Even though the primary outcome, based on infected subjects, failed to reach a statistically significant difference between the intervention groups, vaccinated individuals who consumed BioGaia Protectis showed significantly increased IgA antibody levels when 28 days or more had elapsed from vaccination. The study was conducted at the Nutrition-Gut-Brain Interactions Research Centre, Örebro University, Sweden. The results suggest that BioGaia Protectis may improve long-term protection against breakthrough infections after vaccination. The same type of antibodies that are increased by probiotics in this study have previously been shown to be protective against breakthrough infections. 
